









Markets
/
Stocks
/
nasdaq-omcl
/

Omnicell Inc

OMCL

35.371USD

-0.189-0.53%

Market hours （ET）Quotes delayed by 15 min

1.59BMarket Cap

79.68P/E TTM



Omnicell Inc

35.371

-0.189-0.53%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Omnicell Inc

Currency: USD Updated: 2025-11-13

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Omnicell Inc's Score

Industry at a Glance

Industry Ranking

11 / 209

Overall Ranking

52 / 4603

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Buy

Current Rating

47.333

Target Price

+28.41%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Omnicell Inc Highlights

StrengthsRisks

Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care through a portfolio of robotics, smart devices, intelligent software, and services. Its point of care automation solutions is designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Company’s XT Series automated dispensing systems for medications and supplies, which are used in nursing units and other clinical areas of the hospital, are designed to support workflows specific to each area of the hospital, with various software and hardware options. For the operating room, the Company also offer specialized automated dispensing systems.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 1.11B.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 82.27, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 48.76M shares, decreasing 13.49% quarter-over-quarter.

Held by Keeley-Teton Advisors, LLC

Star Investor Keeley-Teton Advisors, LLC holds 25.80K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-13

The company's current financial score is 8.87, which is higher than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 310.63M, representing a year-over-year increase of 9.99%, while its net profit experienced a year-over-year increase of 36.71%.

Score

Industry at a Glance

Previous score

8.87

Change



Financials

8.25

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.61

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.49

Key Metrics

Free cash flow

No Data

Omnicell Inc's Company Valuation

Currency: USD Updated: 2025-11-13

The company’s current valuation score is 7.55, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is 82.27, which is 477.45% below the recent high of 475.04 and 335.15% above the recent low of -193.44.

Score

Industry at a Glance

Previous score

7.55

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 11/209

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-13

The company’s current earnings forecast score is 7.25, which is lower than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Omnicell Inc is 44.50, with a high of 63.00 and a low of 36.00.

Score

Industry at a Glance

Previous score

7.25

Change

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts

Buy

Current Rating

47.333

Target Price

+28.41%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Omnicell Inc

OMCL

Boston Scientific Corp

BSX

Intuitive Surgical Inc

ISRG

Edwards Lifesciences Corp

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-13

The company’s current price momentum score is 8.94, which is higher than the Healthcare Equipment & Supplies industry's average of 7.00. Sideways: Currently, the stock price is trading between the resistance level at 39.02 and the support level at 30.60, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.22

Change

-0.28

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.791

Buy

RSI(14)

62.890

Neutral

STOCH(KDJ)(9,3,3)

73.821

Sell

ATR(14)

1.555

High Vlolatility

CCI(14)

63.623

Neutral

Williams %R

23.159

Buy

TRIX(12,20)

0.758

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

36.404

Sell

MA10

35.496

Sell

MA20

33.106

Buy

MA50

31.880

Buy

MA100

31.088

Buy

MA200

32.219

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-13

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.43. The latest institutional shareholding proportion is 108.63%, representing a quarter-over-quarter increase of 1.63%. The largest institutional shareholder is The Vanguard, holding a total of 5.59M shares, representing 12.46% of shares outstanding, with 3.94% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

6.82M

-1.72%

The Vanguard Group, Inc.

Star Investors

5.62M

+0.97%

Dimensional Fund Advisors, L.P.

2.17M

+14.97%

State Street Investment Management (US)

2.09M

-3.37%

Lazard Asset Management, L.L.C.

1.71M

+3.81%

Cadian Capital Management LP

1.66M

D. E. Shaw & Co., L.P.

1.42M

+1.85%

Amova Asset Management Co., Ltd.

1.42M

+1.26%

Macquarie Investment Management

1.36M

+19.02%

Geode Capital Management, L.L.C.

1.20M

+2.63%

Risk Assessment

Currency: USD Updated: 2025-11-13

The company’s current risk assessment score is 7.09, which is higher than the Healthcare Equipment & Supplies industry's average of 4.73. The company's beta value is 0.83. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.